These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11726961)

  • 1. alpha-synuclein and cytosolic dopamine: stabilizing a bad situation.
    Sulzer D
    Nat Med; 2001 Dec; 7(12):1280-2. PubMed ID: 11726961
    [No Abstract]   [Full Text] [Related]  

  • 2. Alpha-synuclein and neurodegenerative diseases.
    Goedert M
    Nat Rev Neurosci; 2001 Jul; 2(7):492-501. PubMed ID: 11433374
    [No Abstract]   [Full Text] [Related]  

  • 3. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
    Conway KA; Rochet JC; Bieganski RM; Lansbury PT
    Science; 2001 Nov; 294(5545):1346-9. PubMed ID: 11701929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein.
    Lotharius J; Brundin P
    Nat Rev Neurosci; 2002 Dec; 3(12):932-42. PubMed ID: 12461550
    [No Abstract]   [Full Text] [Related]  

  • 5. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
    Auluck PK; Chan HY; Trojanowski JQ; Lee VM; Bonini NM
    Science; 2002 Feb; 295(5556):865-8. PubMed ID: 11823645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease.
    Sidhu A; Wersinger C; Vernier P
    FEBS Lett; 2004 May; 565(1-3):1-5. PubMed ID: 15135042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-synuclein in Lewy bodies.
    Spillantini MG; Schmidt ML; Lee VM; Trojanowski JQ; Jakes R; Goedert M
    Nature; 1997 Aug; 388(6645):839-40. PubMed ID: 9278044
    [No Abstract]   [Full Text] [Related]  

  • 9. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Could a loss of alpha-synuclein function put dopaminergic neurons at risk?
    Perez RG; Hastings TG
    J Neurochem; 2004 Jun; 89(6):1318-24. PubMed ID: 15189334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?
    Maguire-Zeiss KA; Short DW; Federoff HJ
    Brain Res Mol Brain Res; 2005 Mar; 134(1):18-23. PubMed ID: 15790526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-synuclein: normal function and role in neurodegenerative diseases.
    Norris EH; Giasson BI; Lee VM
    Curr Top Dev Biol; 2004; 60():17-54. PubMed ID: 15094295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
    Jellinger KA
    Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
    Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A
    Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commentary on "Alpha-synuclein and mitochondria: a tangled skein".
    Beal MF
    Exp Neurol; 2004 Apr; 186(2):109-11. PubMed ID: 15026249
    [No Abstract]   [Full Text] [Related]  

  • 16. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
    Dong Z; Ferger B; Feldon J; Büeler H
    J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synucleins and their relationship to Parkinson's disease.
    von Bohlen Und Halbach O
    Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.
    Xu J; Kao SY; Lee FJ; Song W; Jin LW; Yankner BA
    Nat Med; 2002 Jun; 8(6):600-6. PubMed ID: 12042811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropathological spectrum of synucleinopathies.
    Jellinger KA
    Mov Disord; 2003 Sep; 18 Suppl 6():S2-12. PubMed ID: 14502650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine induces autophagic cell death and alpha-synuclein increase in human neuroblastoma SH-SY5Y cells.
    Gómez-Santos C; Ferrer I; Santidrián AF; Barrachina M; Gil J; Ambrosio S
    J Neurosci Res; 2003 Aug; 73(3):341-50. PubMed ID: 12868068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.